Relmada Therapeutics Inc (RLMD) - Total Liabilities
Based on the latest financial reports, Relmada Therapeutics Inc (RLMD) has total liabilities worth $7.49 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore how fast is Relmada Therapeutics Inc growing its equity to track the company's year-over-year net asset growth rate.
Relmada Therapeutics Inc - Total Liabilities Trend (2012–2025)
This chart illustrates how Relmada Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data.
Relmada Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Relmada Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shandong Xiantan Co Ltd
SHE:002746
|
China | CN¥3.57 Billion |
|
OCI NV
AS:OCI
|
Netherlands | €1.67 Billion |
|
Nanjing Hongbaoli Corp Ltd
SHE:002165
|
China | CN¥3.36 Billion |
|
Kossan Rubber Industries Bhd
KLSE:7153
|
Malaysia | RM352.84 Million |
|
Ferroglobe PLC
NASDAQ:GSM
|
USA | $850.63 Million |
|
Guangzhou Hangxin Aviation Technology Co Ltd
SHE:300424
|
China | CN¥1.76 Billion |
|
Logistea AB Series B
ST:LOGI-B
|
Sweden | Skr9.63 Billion |
|
Baticim Bati Anadolu Cimento Sanayi AS
IS:BTCIM
|
Turkey | TL10.45 Billion |
Liability Composition Analysis (2012–2025)
This chart breaks down Relmada Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Relmada Therapeutics Inc market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 14.62 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Relmada Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Relmada Therapeutics Inc (2012–2025)
The table below shows the annual total liabilities of Relmada Therapeutics Inc from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $7.49 Million | -27.24% |
| 2024-12-31 | $10.30 Million | -15.57% |
| 2023-12-31 | $12.19 Million | -2.20% |
| 2022-12-31 | $12.47 Million | -17.21% |
| 2021-12-31 | $15.06 Million | +19.50% |
| 2020-12-31 | $12.60 Million | +764.53% |
| 2019-12-31 | $1.46 Million | -82.97% |
| 2018-12-31 | $8.56 Million | +521.89% |
| 2017-12-31 | $1.38 Million | -57.00% |
| 2016-12-31 | $3.20 Million | -79.45% |
| 2015-12-31 | $15.58 Million | 0.00% |
| 2014-12-31 | $15.58 Million | -42.01% |
| 2014-06-30 | $26.87 Million | 0.00% |
| 2013-12-31 | $26.87 Million | +384025.37% |
| 2012-12-31 | $7.00K | -- |
About Relmada Therapeutics Inc
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, whic… Read more